Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index
- Authors
- Persano, M.[Persano, M.]; Rimini, M.[Rimini, M.]; Tada, T.[Tada, T.]; Suda, G.[Suda, G.]; Shimose, S.[Shimose, S.]; Kudo, M.[Kudo, M.]; Cheon, J.[Cheon, J.]; Finkelmeier, F.[Finkelmeier, F.]; Lim, H.Y.[Lim, H.Y.]; Presa, J.[Presa, J.]; Masi, G.[Masi, G.]; Yoo, C.[Yoo, C.]; Lonardi, S.[Lonardi, S.]; Pressiani, T.[Pressiani, T.]; Piscaglia, F.[Piscaglia, F.]; Kumada, T.[Kumada, T.]; Rimassa, L.[Rimassa, L.]; Scartozzi, M.[Scartozzi, M.]; Cascinu, S.[Cascinu, S.]; Casadei-Gardini, A.[Casadei-Gardini, A.]; HCC COLLABORATIVE GROUP[HCC COLLABORATIVE GROUP]
- Issue Date
- 1-Apr-2023
- Publisher
- International Institute of Anticancer Research
- Keywords
- ABE index; advanced hepatocellular carcinoma; atezolizumab plus bevacizumab; recursive partitioning analysis
- Citation
- Anticancer Research, v.43, no.4, pp.1599 - 1610
- Indexed
- SCIE
SCOPUS
- Journal Title
- Anticancer Research
- Volume
- 43
- Number
- 4
- Start Page
- 1599
- End Page
- 1610
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/103670
- DOI
- 10.21873/anticanres.16310
- ISSN
- 0250-7005
- Abstract
- Background/Aim: The purpose of this study was to ascertain a novel prognostic index via recursive partitioning analysis (RPA) in hepatocellular carcinoma (HCC) patients being treated with the combination of atezolizumab plus bevacizumab (ABE) in first-line setting. Patients and Methods: A total of 784 patients with HCC were included in the analysis. Results: RPA identified three groups of patients: high-risk [Child-Pugh B (CP-B) patients; CP-A and Albumin-Bilirubin (ALBI)-2 patients; CP-A and ALBI-1 patients with macrovascular invasion (MVI), and alpha-fetoprotein (α-FP) ≥400 ng/ml]; intermediate-risk [CP-A and ALBI-1 patients with aspartate aminotransferase (AST) normal value (NV), and αFP ≥400 ng/ml, but without MVI; CP-A and ALBI-1 patients with AST increased value (IV), and neutrophil-lymphocyte ratio (NLR) ≥3, but without MVI]; low-risk (CP-A and ALBI-1 patients with AST NV, and αFP <400 ng/ml, but without MVI; CP-A and ALBI-1 patients with AST IV, and NLR <3, but without MVI; CP-A and ALBI-1 patients with MVI, and αFP <400 ng/ml). Overall survival was 7.0 months in high-risk patients (20.8%), 14.2 months in intermediate-risk patients (19.1%), and 22.5 months in low-risk patients (60.1%). Conclusion: The ABE index allows for easy stratification of HCC patients treated with the combination of ABE in first-line setting. © 2023 International Institute of Anticancer Research. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.